Inflammatory biomarkers such as C-Reactive Protein (CRP), myocardial fibrosis, and hypertrophy biomarkers such as Matrix Metalloproteinase-9 (MMP9) and soluble Suppression of Tumorigenicity 2 (sST2) have been introduced as promising biomarkers for LVR prediction [6, 11]. This evidence concerns the gene MMP9 and Myocardial fibrosis.